ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on December 19, 2013, reporting events that occurred on December 13, 2013. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved the following compensation changes effective for the 2014 fiscal year and retroactive bonuses for 2013:
- 2014 Base Salaries: Adam S. Grossman ($450,000), Brian Lenz ($320,000), and Dr. James Mond ($325,000).
- 2013 Bonuses Approved: Adam S. Grossman ($125,000), Brian Lenz ($79,568), and Dr. James Mond ($53,560).
- 2014 Bonus Targets: Established as a percentage of base salary: Adam S. Grossman (50%), Brian Lenz (35%), and Dr. James Mond (35%).
Guidance, Outlook, and Risks
The filing outlines that 2014 bonus payouts are contingent upon the achievement of both corporate and individual performance objectives determined by the Board. The Compensation Committee will approve all payouts based on management recommendations regarding individual performance. No specific financial guidance, risks, or contingencies regarding the company's operations were disclosed in this report.
Key Facts for Investor Verification
- Verify the total cash compensation impact of the approved 2013 bonuses and 2014 salary increases on the company's operating expenses.
- Confirm the specific corporate performance objectives required to trigger the 2014 bonus targets.
- Review subsequent filings to determine if the 2013 bonuses were paid and if the 2014 performance targets were met.